Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1, Open-Label, Dose-Escalation, Safety and Tolerability Study of INCAGN02390 in Participants With Select Advanced Malignancies

NCT03652077 is registered in ClinicalTrials.gov with Incyte Corporation as lead sponsor.

NCT NCT03652077
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03652077 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1, Open-Label, Dose-Escalation, Safety and Tolerability Study of INCAGN02390 in Participants With Select Advanced Malignancies
Lead sponsor
Incyte Corporation
Phase
Phase 1
Overall status
Completed
Start date
September 24, 2018
Completion date
August 18, 2021
Enrollment
40 (actual)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

cervical cancer, esophageal cancer, gastric cancer, gastroesophageal junction cancer, hepatocellular carcinoma, melanoma, merkel cell carcinoma, mesothelioma, mismatch repair deficiency, msi, non-small cell lung cancer, nsclc, ovarian cancer, rcc, renal cell carcinoma, small cell lung cancer, squamous cell carcinoma of the head and neck, stomach cancer, triple-negative breast cancer, urothelial carcinoma, uveal melanoma